AstraZeneca Launches Targeted Lung Cancer Drug In US After FDA Accelerated Approval
AstraZeneca’s Zegfrovy demonstrated a 46% overall response rate in a trial supporting its accelerated FDA approval, as the…
#EuropeSays #Britain #Europe #EU #AstraZeneca #AstraZenecaPLC #AstraZenecashares #AstraZenecastock #AZN #AZNLatestNews #AZNshares #AZNstock
https://www.europesays.com/britain/149269/